WELCOME!
to IMGT/mAb-DB
THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®
IMGT
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF


IMGT/mAb-DB ID 833
INN
INN Number
INN Prop. List
INN Rec. List
Common name neihulizumab, AbGn-168H
Proprietary name
Species Humanized
IMGT receptor type IG
Format (legend)
Receptor identification
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB
IMGT/3Dstructure-DB
Specificity target name and species SELPLG (selectin P ligand, selectin P glycoprotein ligand, PSGL-1, CD162) [Humanized]
Development Technology
Origin clone species
Origin clone name

Company AbGenomics International, Inc (Los Altos CA USA)
Expression system
Application Therapeutic
Clinical domain Immunology
Mechanism of action
Clinical indication Graft-versus-host disease (GvHD)
Development status Phase II
Regulatory agency status and year

Company AbGenomics International, Inc (Los Altos CA USA)
Expression system
Application Therapeutic
Clinical domain Immunology
Mechanism of action
Clinical indication Colitis, ulcerative (UC)
Development status Phase II
Regulatory agency status and year

    Company AbGenomics International, Inc (Los Altos CA USA)
    Expression system
    Application Therapeutic
    Clinical domain Immunology
    Mechanism of action
    Clinical indication Psoriatic arthritis (PSA)
    Development status Phase II
    Regulatory agency status and year

      Clinical trials 10 studies found, 3 recruiting
      Authority decisions
        External links
        Biosimilars
          Format legend:

          © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
          European Commission umontpellier CNRS